Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Increased by Financial Counselors Inc.

Financial Counselors Inc. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,887 shares of the biopharmaceutical company’s stock after purchasing an additional 274 shares during the period. Financial Counselors Inc.’s holdings in Gilead Sciences were worth $821,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in GILD. HHM Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new stake in Gilead Sciences during the fourth quarter valued at $28,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences in the fourth quarter valued at about $29,000. Crews Bank & Trust purchased a new stake in shares of Gilead Sciences during the 4th quarter worth about $31,000. Finally, Stephens Consulting LLC lifted its holdings in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 260 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.6 %

NASDAQ GILD opened at $111.79 on Friday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The stock has a market cap of $139.22 billion, a PE ratio of 302.14, a PEG ratio of 0.71 and a beta of 0.21. The firm has a 50-day simple moving average of $105.48 and a 200 day simple moving average of $94.81.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.83%. The ex-dividend date was Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 854.05%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research reports. Wells Fargo & Company increased their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. BMO Capital Markets raised their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Oppenheimer upped their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday, March 4th. Bank of America boosted their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $105.12.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last 90 days, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.